Drug Search Results
More Filters [+]

LR-20062

Alternative Names: LR-20062, LR 20062, LR20062
Latest Update: 2024-09-30
Latest Update Note: Clinical Trial Update

Product Description

LR20062' is a vaccine that prevents six infections, including diphtheria, tetanus, whooping cough, polio, hemophilus influenzae, and hepatitis B. Compared to the commonly used combination of the pentavalent vaccine and hepatitis B vaccine, the number of inoculations has been reduced by two (6 times → 4 times). (Sourced from: https://www.mk.co.kr/en/it/11091904)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: LG Chem
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LR-20062

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title